The Company is a biopharmaceutical enterprise developing pharmaceutical and therapeutic products, with its principal asset being Lucid-MS, an exclusive licensed compound from the University Health Network targeting progressive multiple sclerosis in competition with established treatments. The Company operates in the competitive pharmaceutical and biotechnology industry but has not yet generated revenue from product sales; instead, it depends on successful clinical development, regulatory approval, and commercialization of its candidates, funded through equity, debt securities, and other financial activities. Commercial success depends on multiple factors including therapeutic efficacy, regulatory approval from the FDA and Health Canada, market acceptance by physicians and payors, manufacturing capacity, and ability to compete against well-capitalized pharmaceutical and biotechnology firms.